This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stryjewski, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stryjewski, M. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2006, p. 862-867, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.862-867.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

Martin E. Stryjewski,1,2* Vivian H. Chu,1,2 William D. O'Riordan,3,4 Brian L. Warren,5 Lala M. Dunbar,6 David M. Young,7 Marc Vallée,2 Vance G. Fowler Jr.,1,2 Joel Morganroth,8,9 Steven L. Barriere,10 Michael M. Kitt,10 G. Ralph Corey,1,2 for the FAST 2 Investigator Group

Division of Infectious Diseases, Duke University Medical Center,1 Duke Clinical Research Institute, Durham, North Carolina,2 Paradise Valley Hospital, National City,3 e-StudySite, San Diego, California,4 Department of Surgery, Tygerberg Hospital and University of Stellenbosch, Tygerberg, South Africa,5 Louisiana State University Medical Center, New Orleans, Louisiana,6 San Francisco General Hospital/UCSF, San Francisco, California,7 University of Pennsylvania School of Medicine,8 eResearchTechnology, Inc., Philadelphia, Pennsylvania,9 Theravance, Inc., South San Francisco, California,10

Received 1 July 2005/ Returned for modification 4 August 2005/ Accepted 9 December 2005

Telavancin is a bactericidal lipoglycopeptide with a multifunctional mechanism of action. We conducted a randomized, double blind, active-control phase II trial. Patients ≥18 years of age with complicated skin and skin structure infections caused by suspected or confirmed gram-positive organisms were randomized to receive either telavancin at 10 mg/kg intravenously every 24 h (q24h) or standard therapy (antistaphylococcal penicillin at 2 g q6h or vancomycin at 1 g q12h). A total of 195 patients were randomized and received at least one dose of study medication. Clinical success rates were similar in all analysis populations at test of cure. In microbiologically evaluable patients with Staphylococcus aureus at baseline (n = 91), 96% of the telavancin group and 90% of the standard-therapy group were cured. Among patients with methicillin-resistant S. aureus (MRSA) at baseline (n = 45), clinical cure rates were also 96% for telavancin and 90% for standard therapy. Microbiologic eradication in patients with S. aureus infection was better with telavancin compared to standard therapy (92% versus 78%, P = 0.07) and significantly better in patients with MRSA (92% versus 68%; P = 0.04). Therapy was discontinued for an adverse event (AE) in 6% and 3% of the patients receiving telavancin and standard therapy, respectively. Except for two cases of rash in the telavancin group, these AEs were similar in type and severity in the two groups. The overall incidences and severities of AEs and laboratory abnormalities were similar between the two groups. These data support the ongoing studies assessing the efficacy and safety of telavancin in the treatment of serious gram-positive infections, particularly involving MRSA.

* Corresponding author. Mailing address: Azcuenaga 1757, Apt. 1C, Capital Federal (C1128AAC), Buenos Aires, Argentina. Phone: 54-114-803-1358. Fax: 54-114-803-1358. E-mail: stryj001{at}mc.duke.edu.

Antimicrobial Agents and Chemotherapy, March 2006, p. 862-867, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.862-867.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Svetitsky, S., Leibovici, L., Paul, M. (2009). Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis. Antimicrob. Agents Chemother. 53: 4069-4079 [Abstract] [Full Text]  
  • Kosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies. Antimicrob. Agents Chemother. 53: 4217-4224 [Abstract] [Full Text]  
  • Lunde, C. S., Hartouni, S. R., Janc, J. W., Mammen, M., Humphrey, P. P., Benton, B. M. (2009). Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II. Antimicrob. Agents Chemother. 53: 3375-3383 [Abstract] [Full Text]  
  • Nannini, E. C., Stryjewski, M. E., Singh, K. V., Bourgogne, A., Rude, T. H., Corey, G. R., Fowler, V. G. Jr., Murray, B. E. (2009). Inoculum Effect with Cefazolin among Clinical Isolates of Methicillin-Susceptible Staphylococcus aureus: Frequency and Possible Cause of Cefazolin Treatment Failure. Antimicrob. Agents Chemother. 53: 3437-3441 [Abstract] [Full Text]  
  • LaPlante, K. L., Mermel, L. A. (2009). In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains. Antimicrob. Agents Chemother. 53: 3166-3169 [Abstract] [Full Text]  
  • Darouiche, R. O., Mansouri, M. D., Schneidkraut, M. J. (2009). Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits. Antimicrob. Agents Chemother. 53: 2626-2628 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Pankuch, G. A., Appelbaum, P. C. (2009). Postantibiotic Effects of Telavancin against 16 Gram-Positive Organisms. Antimicrob. Agents Chemother. 53: 1275-1277 [Abstract] [Full Text]  
  • Wong, S. L., Barriere, S. L., Kitt, M. M., Goldberg, M. R. (2008). Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 62: 780-783 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62: 116-121 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 2383-2388 [Abstract] [Full Text]  
  • Campbell, S. J., Deshmukh, H. S., Nelson, C. L., Bae, I.-G., Stryjewski, M. E., Federspiel, J. J., Tonthat, G. T., Rude, T. H., Barriere, S. L., Corey, R., Fowler, V. G. Jr. (2008). Genotypic Characteristics of Staphylococcus aureus Isolates from a Multinational Trial of Complicated Skin and Skin Structure Infections. J. Clin. Microbiol. 46: 678-684 [Abstract] [Full Text]  
  • Moellering, R. C. Jr (2008). A 39-Year-Old Man With a Skin Infection. JAMA 299: 79-87 [Abstract] [Full Text]  
  • Gotfried, M. H., Shaw, J.-P., Benton, B. M., Krause, K. M., Goldberg, M. R., Kitt, M. M., Barriere, S. L. (2008). Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics. Antimicrob. Agents Chemother. 52: 92-97 [Abstract] [Full Text]  
  • Noel, G. J., Strauss, R. S., Amsler, K., Heep, M., Pypstra, R., Solomkin, J. S. (2008). Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 37-44 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Jansen, W. T. M., Verel, A., Verhoef, J., Milatovic, D. (2007). In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe. Antimicrob. Agents Chemother. 51: 3420-3424 [Abstract] [Full Text]  
  • Saravolatz, L. D., Pawlak, J., Johnson, L. B. (2007). Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 60: 406-409 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., de-Lazzari, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez-de-Anta, M.-T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2007). Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377 [Abstract] [Full Text]  
  • Barcia-Macay, M., Lemaire, S., Mingeot-Leclercq, M.-P., Tulkens, P. M., Van Bambeke, F. (2006). Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 1177-1184 [Abstract] [Full Text]  
  • (2006). Telavancin: A New Antibiotic for Complicated Skin Infections. Journal Watch Dermatology 2006: 3-3 [Full Text]  
  • (2006). Telavancin: A New Antibiotic for Complicated Skin Infections. JWatch Infect. Diseases 2006: 8-8 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»